UBS initiated coverage of Acadia Pharmaceuticals with a Buy rating and $33 price target. The firm’s bullish thesis is based on launch acceleration for Daybue and potential indication expansion for Nuplazid, both in debilitating diseases where no other drug works, the analyst tells investors in a research note. The firm estimates Daybue can generate peak sales of $900M and models a 43% CAGR for 4-year forward sales growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD: